DOCSLIB.ORG

15-CLASSIFICATION of DRUG Adrenergic Nonsel Αadr Antag

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
15-CLASSIFICATION of DRUG Adrenergic Nonsel Αadr Antag 15-CLASSIFICATION OF DRUG Adrenergic nonsel αadr antag-dibenamine, ergot alkaloid(ergotamine, ergosine, ergocornine, ergocristine, ergocryptine), phenoxybenzamine(irrevers), phentolamine, tolazoline sel α1adr agonist-mephentermine, metaraminol, phenylephrine, methoxamine, midodrine, naphazoline, oxymetazoline, xylometazoline sel α1adr antag-prazosin, indoramin, terazosin, doxazosin, alfuzosin, tamsulosin, silodosin, urapidil sel α2adr agonist-apraclonidine, clonidine, methyldopa, guanfacine, guanabenz, moxonidine, rilmonidine, brimonidine, tizanidine, dexmedetomidine sel α2adr antag-yohimbine, idazoxan, mianserine, mirtazapine, tianeptine, amineptine nonsel βadr agonist-isoprenaline nonsel βadr antag-pindolol(intrinsic sympathomimetic activity, max bioavail), Nadolol(loNgest), propranolol(max LA activity), oxprenolol, timolol sel β1adr agonist-dobutamine sel β1adr antag-eSmolol(Shortest), atenolol(min prot binding), metoprolol(max interindividual variation), acebutolol, bisoprolol, celiprolol, nebivolol(3rd gen), betaxolol sel β2adr agonist-terbutaline, ritodrine, orciprenaline(metaproterenol), salbutamol(albuterol), salmeterol, fenoterol, isoetharine, dopexamine(β2,D1) sel β2adr antag-butoxamine sel β3adr agonist-sibutramine Adrenocortical suppression steroid(prednisone, hydrocortisone, dexamethasone), aminoglutethimide, fludrocortisone, ketoconazole, megestrol, metyrapone, mitotane Alzheimer ds antiAChE synth-tacrine, donepezil, rivastigmine, eptastigmine, metrifonate natural-galantamine antioxidant-vitD,E MAOI-selegiline acetyl L carnitine antiinflammatory-NSAID(piracetam-nootropic) pleotropic(antiinflammat+antiproliferat)-statinAim4aiims.in NMDA antag-memantine monocloAb-babineuzumab(βamyloid) Gingko biloba γsecretas inh-semegarcestat, tarenfluril antiAnginal vasodilator NO3 short-amylNO3, glycerylNO3 intermeD-isosorbide DiNO3 loNg(6-10h)-isosorbide moNoNO3(least 1st pass metab) longest(12h)-pentaerythritol tetraNO3 newer-molsidone K ch opener-nicorandil CCB phenylalkylamine-verapamil benzothiazepine 1,4dihydropyridine-nifedipine, nicardipine, isradipine, felodipine, amlodipine oxyfedrine cardiac depressant CCB βadr antag Na ch blocker-ivabradine modify substrate utilization FA oxidat inh(pFOX)-trimetazidine, ranolazine Antibiotic Gram+ve bact penicillin penicillinG&ester-penicillinG(benzyl penicillin), procaine penicillinG, benzathine penicillinG acid resist-phenoxymethylpenicillin(penicillinV), phenoxyethylpenicillin(phenethicillin), acidocillin penicillinase resist acid labile-methicillin, nafcillin, oxacillin, cloxacillin, dicloxacillin acid resist-flucloxacillin G+ve&G–ve-ampicillin(polar), becampicillin, talampicillin, pivampicillin, amoxycillin extended spectrum antipseudomonal carboxypenicillin-carbenicillin, ticarcillin ureidopenicillin-piperacillin, mezlocillin, azlocillin amidopenicillin-mecillinam, pivmecillinam βlactamase inh-Amoxycillin+clavulinic acid(Augmentin), Ticarcillin+clavulinic acid(Timentin),Aim4aiims.in sulbactam, tazobactam macrolide erythromycin, spiramycin, oleandomycin, triacetyloleandomycin newer macrolide-roxithromycin, telithromycin, azithromycin, clarithromycin lincosamide-lincomycin, clindamycin glycopeptide-vancomycin, teicoplanin, oritavancin, telavancin, dalbavancin oxazolidinone-linezolid streptogramin-quinupristine, dalfopristine other-daptomycin, novobiocin, fucidin, bacitracin, mupirocin Gram–ve bact aminoglycoside-amikacin, neomycin, streptomycin, kanamycin, gentamicin, tobramycin, framycetin(soframycin), paromomycin, netilmicin non aminoglycoside-colistin, polymyxinB, tyrothricin, cycloserine, spectinomycin, fosfomycin monobactam-aztreonam both G+ve,G–ve nitrofuran-nitrofurantoin, furazolidone, nifuroxime, nitrofurazone cephalosporin gen I O-cefalexin, cefadroxil P-cefazolin gen II O-cefaclor, cefuroxime, loracarbef P-cefamandole, cefoxitin, cefuroxime, cefamycin gen III O-cefixime, cefopodoxime P-cefotaxime, ceftriaxone, ceftizoxime, ceftazidime, cefaperazone gen IV-cefepime, cefelidine, cefpirome gen V P-ceftobipirole, ceftraraline rifamycin carbapenem-imipenem, meropenem, ertapenem, doripenem, faropenem both+Rickettsia+Chlamydia(broad spectrum) tetracycline I-tetracycline, oxytetracycline, chlortetracycline II-lymecycline, demeclocycline III-doxycycline, minocycline demethylchlortetracycline, methacycline, tigecycline chloramphenicol acidfastAim4aiims.in bact rifamycin B-rifampicin S-rifabutin rifaximin viomycin quinolone nalidixic acid fluoroquinolone-norfloxacin(least oral bioavailability), ofloxacin, lomefloxacin, ciprofloxacin, pefloxacin(c/i liver fail), sparfloxacin, levofloxacin, gatifloxacin, moxifloxacin, gemifloxacin, trovafloxacin other sulfonamide systemic short-sulfadiazine, sulfadimidine(sulfamethazine), sulfacetamide, sulfafurazone(sulfisoxazole), sulfamethizole intermediate-sulfamethoxazole long(XI)-sulfadoXIne, sulformethoXIne, sulfamethoXYpyridazine, sulfadimethoXIne ulcerative colitis-sulfasalazine topical-mafenide, sulfacetamide, Ag sulfadiazine fungi antibiotic-griseofulvin, amphotericinB, nystatin antimetab-flucytosine azole iMidazole(MECK)-Miconazol, Econazole, Clotrimazole, Ketoconazole triazole-fluconazole, itraconazole, posaconazol, ravuconazol, voriconazole echinocandin-caspofungin, micafungin, anidulafungin misc-terbinafine parasite antimalaria cinchona alkaloid-quinine, quinidine quinoline derivative 4aminoquinoline-hydroxychloroquine, chloroquine, amodiaquine, amopyroquine, pyronaridine 8aminoquinoline(BPT)-Bulaquine, Primaquine, Tafeloquine quinoline methanol-mefloquine, halofantrine, lumefantrine acridine-mepacrine antifolate biguanide-proguanil diaminopyridine-pyrimethamine, sulfonamide, trimethoprim Aim4aiims.in artemisinin H2O Soluble-arteSunate lipid soluble-artether, artemether antimicrobial-doxycycline, clindamycin, atovaquone amoeba emetine-emetine, dehydroemetine imidazole-metronidazole, tinidazole, secnidazole, ornidazole quinoline-diiodohydroxyquinoline, iodochlorohydroxyquinoline, chloroquine antibiotic-tetracycline, paromomycin misc-diloxanide furoate, nitazoxanide, kurchi leishmaniasis pentavalent antimony-meglumine antimonate, Na stibogluconate diamidine-dihydroxystibamidine isethionate, pentamidine isethionate misc-amphotericinB, aminocidin, miltefosine, paromomycin, sitamaquine fumagillin virus compound interfere with nucleic acid-idoxuridine, adenine arabinoside, acyclovir, valacyclovir, famciclovir, ganciclovir, foscarnet Na, sorivudine, ribavirin, trifluridine, azidothymidine attachm/penetrat inh-amantadine, rimantadine, zanamivir(poorest oral bioavail, IN), oseltamivir(neuraminidase inh) reverse transcriptase inh-lamivudine immune mech-IFN, γglobulin, monoclonal Ab(palivizumab) misc-docosanol, fomivirsen Anxiolytic BDZ chlormethiazol 5HT1A agonist-buspirone, gepirone, ipsapirone, trospirone βadr antag-propranolol SSRI H1 antag-hydroxyzine Vaughan William classif antiArrhythmic drug(SBPC) class I-Na ch blocker Ia(block Na,K)-Quinidine, Procainamide, Disopyramide(highest antivagal)(Q Phir Diya) Ib(block Na,open K)-Tocainamide, Phenytoin, Lignocaine, Mexiletine(Tera Pyara Lock Mujhe) Ic(block Na)-Flecainide, Propafenone(Faltu Pyare), moricizine classII-Bet adr antag classIII-K ch blocker-dofetilide, ibutilide, amiodarone, dronedarone, bretylium, sotalol classIV-CaAim4aiims.in ch blocker misc-multi ion blocker-vernakalant atrial arrhythm(VAD)-Verapamil, Adenosine, Digoxin(NaK pump antag, vagomimetic) ventric arrhythm-IB both-other ART indication <1y-CD4<1500cell/mm³ 3-5y-CD4<350cell/mm³ >5y-CD4<200cell/mm³ NsRTI-ADR-lactic acidosis zidovudine(ADV/AZT)-M.C, prevent vertic transmis fr 25.5→ 8%, prophylax of needle-stick inj, ADR-macrocytic anem(myelosuppression), neutropenia, nail hyperpigmentat(blue), lipoatrophy, mitoch myopathy with ragged red fibr, hepatomegaly didanosine(ddl)-ADR-painful sens neuropathy(MC), diarrh, pancreatitis(max) zalcitabine(ddc)-weakest NRTI, ADR-periph sens neuropathy stavudine(D4t)-ADR-lipodystrophy(max), periph sens neuropathy(max) lamivudine(3TC)-best tolerated, no neuropathy/pancreatitis, used in HBV emtricitabine(FTc)-HBV abacavir-metab by alc DH, ADR-HSR(HLA-B5701), severe hyperlipidemia(MI) NtRTI-Tenofovir-HBV, ADR-GI toxicity, Fanconi synd, hypophosphatemia NNRTI(DEN) Delavirdine(c/i in pregn) Efavirenz(c/i in pregn), ↑liver Enz Nevirapine-ADR-hepatotox(MC), neuropsychos, Steven Jhnsn synd, metab ↑by rifampicin 2nd gen-etravirine, rilpivirine protease inh-ADR-lipodystrophy(Rx-tesmorelin) saquinavir-best tolerat, no enzyme inh Atazanavir-Acid pH for Absorption, ↑PR interval, asympt hyperbilirubinemia amprenavir-nephrolithiasis indinavir-nephrolithiasis(max), cardiac arrhythmia foSamprenavir-Stevens Jhnsn synd ritonavir-ADR-circumoral paresthesia, enzyme inh CYP3A4,3D6(max) nelfinavir lopinavir tipRANavir-ADR-intracRANial hge darunavir CCR5 inh maraviroc aplaviroc-ADR-hepatotoxicity Aim4aiims.invicriviroc fusion inh-enfuvirtide-bind Gp41, SC ADR-inj site rxn,pneum CD4 antag-Ibalizumab maturation inh bevirimab abalicumab integrase strand transfer inh raltegravir elvitegravir dolulstegravir antiAsthmatic bronchodilator β2adr agonist short-salbutamol(albuterol), rimeterol, isoetharine, bitolterol, fenoterol, terbutaline long-Salmeterol(Slow, long), Formoterol(Fast, long), vilenterol, arformoterol, indacaterol, olodaterol, abediterol nonsel βadr agonist-orciprenaline, adrenaline, ephedrine phosphodiesterase inh-methylxanthine[thiophylline, aminophylline, doxophylline(most cardiosafe)] anticholin-ipratropium, thiotropium anti inflammatory drug glucocorticoid(phospholipase A2 inh)-budesonide, fluticasone,
Load more

Recommended publications
  • Determining the Role of Gabaergic Signaling in The
    DETERMINING THE ROLE OF GABAERGIC SIGNALING IN THE CRANIOFACIAL DEVELOPMENT OF LARVAL ZEBRAFISH by LINDSEY L. BEEBE (Under the Direction of James D. Lauderdale) ABSTRACT Although best known as an inhibitory neurotransmitter, intriguing evidence has implicated GABA as a key signaling molecule in craniofacial development in mammals. Glutamate is converted to GABA by an enzyme called glutamic acid decarboxylase (GAD), which exists in two isoforms, GAD67 and GAD65. The GAD1 and GAD2 genes encode these isoforms, respectively. A decrease in GAD activity in the human brain is often associated with epilepsy, schizophrenia and related neurological disorders. In mice and humans, mutations in gad1, but not gad2, result in defects in palate development, and mutations in the Gabrb3 gene, which encodes the β3 subunit of the GABAA receptor, exhibit a comparable phenotype to gad1 mutations. These results suggest that GABA signaling, through the GABAA receptor, can play an important and conserved role in craniofacial development. However, the mechanism of this process is not known and cannot be easily investigated in a mammalian system. In this work, translation-blocking morpholinos against the GAD genes were used to alter expression within the larval zebrafish. While gad2 morphants looked phenotypically normal, gad1 morphant animals exhibited altered cranial structures at 1 and 7 dpf. Yet, both gad1 and gad2 morphants exhibited spontaneous seizure-like neural activity. Through the use of photoactivatable caged-morpholinos, the craniofacial deformities could be bypassed when photolysis was carried out at 24 hpf. Electrophysiological recordings showed that while dark-raised CyHQ-gad1 morphant animals looked phenotypically comparable to wild-type animals, they exhibited abnormal, seizure-like neural activity.
    [Show full text]
  • Neurotransmitters-Drugs Andbrain Function.Pdf
    Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Neurotransmitters, Drugs and Brain Function Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Neurotransmitters, Drugs and Brain Function Edited by R. A. Webster Department of Pharmacology, University College London, UK JOHN WILEY & SONS, LTD Chichester Á New York Á Weinheim Á Brisbane Á Singapore Á Toronto Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Copyright # 2001 by John Wiley & Sons Ltd. Bans Lane, Chichester, West Sussex PO19 1UD, UK National 01243 779777 International ++44) 1243 779777 e-mail +for orders and customer service enquiries): [email protected] Visit our Home Page on: http://www.wiley.co.uk or http://www.wiley.com All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1P0LP,UK, without the permission in writing of the publisher. Other Wiley Editorial Oces John Wiley & Sons, Inc., 605 Third Avenue, New York, NY 10158-0012, USA WILEY-VCH Verlag GmbH, Pappelallee 3, D-69469 Weinheim, Germany John Wiley & Sons Australia, Ltd.
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • Cell Surface Mobility of GABAB Receptors Saad Bin
    Cell surface mobility of GABAB receptors Saad Bin Hannan September 2011 A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy of the University College London Department of Neuroscience, Physiology, and Pharmacology University College London Gower Street London WC1E 6BT UK Declaration ii ‘I, Saad Hannan confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis.' ____________________ Saad Hannan September 2011 To Ammu, Abbu, Polu Abstract ivi Abstract Type-B γ-aminobutyric acid receptors (GABABRs) are important for mediating slow inhibition in the central nervous system and the kinetics of their internalisation and lateral mobility will be a major determinant of their signalling efficacy. Functional GABABRs require R1 and R2 subunit co-assembly, but how heterodimerisation affects the trafficking kinetics of GABABRs is unknown. Here, an α- bungarotoxin binding site (BBS) was inserted into the N-terminus of R2 to monitor receptor mobility in live cells. GABABRs are internalised via clathrin- and dynamin- dependent pathways and recruited to endosomes. By mutating the BBS, a new technique was developed to differentially track R1a and R2 simultaneously, revealing the subunits internalise as heteromers and that R2 dominantly-affects constitutive internalisation of GABABRs. Notably, the internalisation profile of R1aR2 heteromers, but not R1a homomers devoid of their ER retention motif (R1ASA), is similar to R2 homomers in heterologous systems. The internalisation of R1aASA was slowed to that of R2 by mutating a di-leucine motif in the R1 C-terminus, indicating a new role for heterodimerisation, whereby R2 subunits slow the internalization of surface GABABRs.
    [Show full text]
  • The Importance of a Higher Dose of a Mineralocorticoid Receptor Antagonist in Reducing
    CRVASA-544; No. of Pages 4 c o r e t v a s a x x x ( 2 0 1 7 ) e 1 – e 4 Available online at www.sciencedirect.com ScienceDirect journal homepage: http://www.elsevier.com/locate/crvasa Case report The importance of a higher dose of a mineralocorticoid receptor antagonist in reducing risk of recurrent hospitalization in a patient with advanced chronic heart failure – A case report a, a b G. Mairgani *, V. Mála , F. Málek a Odděleni Interna I, Nemocnice Teplice, Krajská zdravotní, a.s., Czech Republic b Kardiocentrum, Nemocnice Na Homolce, Praha, Czech Republic a r t i c l e i n f o a b s t r a c t Article history: The authors present the significance of a higher dose of a mineralocorticoid receptor Received 10 March 2017 antagonist in reducing the frequency of hospitalizations for decompensated heart failure Received in revised form in a 67-year-old patient suffering from advanced chronic heart failure. 9 August 2017 © 2017 The Czech Society of Cardiology. Published by Elsevier Sp. z o.o. All rights reserved. Accepted 19 August 2017 Available online xxx Keywords: Advanced chronic heart failure Mineral corticoid receptor antagonists Eplerenone nervous system and the renin–angiotensin–aldosterone sys- tem (RAAS). The short-term effects include increased heart Introduction activity, vasoconstriction and fluid retention, and the long- term effects are myocyte hypertrophy, apoptosis and myocard Heart failure is defined as a state when the heart is unable to fibrosis (left ventricular remodeling). There is also an increase pump blood with normal venous return according to the needs in the production of vasodilatation mediators (prostaglandins, of tissue metabolism or a state when it is only be able to do so natriuretic peptides, bradykinin and others); however, these with an increased ventricular filling pressure.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0215521 A1 Lalji Et Al
    US 20050215521A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0215521 A1 Lalji et al. (43) Pub. Date: Sep. 29, 2005 (54) MODAFINIL COMBINATION THERAPY FOR Publication Classification IMPROVING SLEEP QUALITY (51) Int. Cl.' .................. A61K 31/724; A61K 31/7008; (76) Inventors: Karim Lalji, Sudbury, MA (US); A61K 31/4164; A61K 31/195; Timothy J. Barberich, Concord, MA A61K 31/165 (US) (52) U.S. Cl. ............................ 514/58; 514/221; 514/389; 514/561; 514/557; 514/23; Correspondence Address: 514/618; 514/469 FOLEY HOAG, LLP PATENT GROUP, WORLD TRADE CENTER WEST (57) ABSTRACT 155 SEAPORT BLVD One aspect of the present invention relates to pharmaceutical BOSTON, MA 02110 (US) compositions comprising a compound that modulates the orexin System and a Sedative agent. In a preferred embodi (21) Appl. No.: 11/018,869 ment, the compound that modulates the orexin System is (22) Filed: Dec. 21, 2004 modafinil and the Sedative agent is eSZopiclone. The phar maceutical compositions of the invention are useful in the Related U.S. Application Data treatment of various sleep disorders. In addition, the present invention relates to a method of treating a patient Suffering (60) Provisional application No. 60/531,822, filed on Dec. from a sleep abnormality or insomnia comprising adminis 22, 2003. Provisional application No. 60/541,684, tering a therapeutically effective amount of a pharmaceutical filed on Feb. 4, 2004. composition of the invention. Patent Application Publication Sep. 29, 2005 Sheet 1 of 2 US 2005/0215521 A1 Figure 1 (RS)-Zopiclone D-Malic Acid Acetone Mixing/Heating Methanol Methanol-DCooling/Crystallizatio (S)-Zopiclone D-Malate See Methanol Filtration/Washing Mother Liquors/Washes -Ge IPC (S)-Zopiclone D-Malate Patent Application Publication Sep.
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • Fluticasone Furoate and Vilanterol for the Treatment of Chronic Obstructive Pulmonary Disease
    Expert Review of Respiratory Medicine ISSN: 1747-6348 (Print) 1747-6356 (Online) Journal homepage: http://www.tandfonline.com/loi/ierx20 Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease Gaetano Caramori, Paolo Ruggeri, Paolo Casolari, Kian Fan Chung, Giuseppe Girbino & Ian M. Adcock To cite this article: Gaetano Caramori, Paolo Ruggeri, Paolo Casolari, Kian Fan Chung, Giuseppe Girbino & Ian M. Adcock (2017): Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease, Expert Review of Respiratory Medicine, DOI: 10.1080/17476348.2017.1386564 To link to this article: http://dx.doi.org/10.1080/17476348.2017.1386564 Accepted author version posted online: 28 Sep 2017. Submit your article to this journal View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ierx20 Download by: [Imperial College London Library] Date: 29 September 2017, At: 01:13 Publisher: Taylor & Francis Journal: Expert Review of Respiratory Medicine DOI: 10.1080/17476348.2017.1386564 Review Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease Gaetano Caramori1*, Paolo Ruggeri1, Paolo Casolari2, Kian Fan Chung3, Giuseppe Girbino1, Ian M. Adcock3. 1Unità Operativa Complessa di Pneumologia, Dipartimento di Scienze Biomediche, Odontoiatriche e delle Immagini Morfologiche e Funzionali (BIOMORF) Università degli Studi di Messina, Italy. 2Centro Interdipartimentale per lo Studio delle Malattie Infiammatorie delle Vie Aeree e Patologie Fumo-correlate (CEMICEF; formerly Centro di Ricerca su Asma e BPCO), Sezione di Medicina Interna e Cardiorespiratoria, Università di Ferrara, Ferrara, Italy. 3Airways Disease Section, National Heart and Lung Institute, Royal Brompton Hospital Biomedical Research Unit, Imperial College London, UK.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • DAS Gabaerge SYSTEM
    DIPLOMARBEIT Titel der Diplomarbeit „In vivo Untersuchung ausgewählter GABAA-Liganden auf das Verhalten von c57Bl/6N-Mäusen“ Verfasserin Sandra Maurer angestrebter akademischer Grad Magistra der Pharmazie (Mag.pharm.) Wien, 2013 Studienkennzahl lt. Studienblatt: A 449 Studienrichtung lt. Studienblatt: Diplomstudium Pharmazie Betreuer: Univ.-Prof. Dr. Steffen Hering DANKSAGUNG In erster Linie möchte ich mich bei Univ. Prof. Dr. Steffen Hering für die Ermöglichung dieser Diplomarbeit am Department für Pharmakologie und Toxikologie, sowie für die Bereitstellung dieses interessanten Themas bedanken. Ein Dankeschön gilt auch Mag. Dr. Sophia Khom für die hilfreichen und kompetenten Ratschläge zum Anfertigen dieser Arbeit. Herzlicher Dank gilt vor allem Mag. Juliane Hintersteiner, die mich bei allen praktischen Arbeiten begleitet, all meine Fragen geduldig beantwortet und mich mit großem Engagement unterstützt hat. Bedanken möchte ich mich weiters bei Mag. Barbara Strommer, die sich für mich eingesetzt hat, diesen Diplomarbeitsplatz zu bekommen. Auch bei meiner Familie möchte ich mich recht herzlich bedanken, dass sie mir das Studium der Pharmazie ermöglichten und mich auch in schwierigen Phasen des Studiums immer unterstützten. Besonderer Dank gilt auch meinem Freund Christoph, der immer an meiner Seite ist. INHALT A) ALLGEMEINER TEIL ................................................................................................................. 1 1. DAS GABAerge SYSTEM .....................................................................................................
    [Show full text]
  • CLINICAL STUDY PROTOCOL Amendment #3
    CLINICAL STUDY PROTOCOL Amendment #3 Document Title: Amendment #3 for a Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study with Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys with Duchenne Muscular Dystrophy (DMD) Protocol Number: VBP15-004 Document Number: VBP15-004-A3 (Version 1.3) FDA IND No.: 118,942 Investigational Product: Vamorolone Sponsor: ReveraGen BioPharma, Inc. 155 Gibbs St. Suite 433 Rockville, MD 20850 Medical Monitors: Outside North America John van den Anker, M.D., Ph.D. Phone: (202) 309 3735 Email: [email protected] North America Benjamin Schwartz, M.D., Ph.D. Phone: (314) 220 7067 Email: [email protected] Document Date: 21 May 2019 This document represents proprietary information belonging to ReveraGen BioPharma, Inc. Unauthorized reproduction of the whole or part of the document by any means is strictly prohibited. This protocol is provided to you as a Principal Investigator, potential Investigator or consultant for review by you, your staff and Institutional Review Board or Independent Ethics Committee. The information contained in this document is privileged and confidential and, except to the extent necessary to obtain informed consent, must not be disclosed unless such disclosure is required by federal or state law or regulations. Persons to whom the information is disclosed in confidence must be informed that the information is confidential and must not be disclosed by them to a third party. Page 1 of 201 ReveraGen
    [Show full text]
  • Low Cerebral Exposure Cannot Hinder the Neuroprotective Effects of Panax Notoginsenosides
    DMD Fast Forward. Published on October 23, 2017 as DOI: 10.1124/dmd.117.078436 This article has not been copyedited and formatted. The final version may differ from this version. DMD # 78436 Low cerebral exposure cannot hinder the neuroprotective effects of panax notoginsenosides Haofeng Li, Jingcheng Xiao, Xinuo Li, Huimin Chen, Dian Kang, Yuhao Shao, Boyu Shen, Zhangpei Zhu, Xiaoxi Yin, Lin Xie, Guangji Wang, Yan Liang Key Lab of Drug Metabolism & Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Tongjiaxiang 24, Nanjing 210009, China Downloaded from dmd.aspetjournals.org at ASPET Journals on September 25, 2021 1 DMD Fast Forward. Published on October 23, 2017 as DOI: 10.1124/dmd.117.078436 This article has not been copyedited and formatted. The final version may differ from this version. DMD # 78436 Running Title Page Panax notoginsenosides exert neuroprotective effects Corresponding author: Yan Liang Co- corresponding author: Guangji Wang Key Lab of Drug Metabolism & Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Tongjiaxiang 24, Nanjing 210009, China. Tel: +86-25-83271060 Email: [email protected] [email protected] H.L. and J.X. contributed equally to this work. Downloaded from Number of text pages: 39 Number of figures: 8 Number of references: 59 dmd.aspetjournals.org Number of words in the Abstract: 217 Number of words in the Introduction: 929 Number of words in the Discussion: 1327 at ASPET Journals on September 25, 2021 Abbreviations:
    [Show full text]